Cargando…

Enabling Anticancer Therapeutics by Nanoparticle Carriers: The Delivery of Paclitaxel

Anticancer drugs, such as paclitaxel (PTX), are indispensable for the treatment of a variety of malignancies. However, the application of most drugs is greatly limited by the low water solubility, poor permeability, or high efflux from cells. Nanoparticles have been widely investigated to enable dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yongjin, Zhang, Bin, Yan, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155358/
https://www.ncbi.nlm.nih.gov/pubmed/21845085
http://dx.doi.org/10.3390/ijms12074395
_version_ 1782210113722908672
author Liu, Yongjin
Zhang, Bin
Yan, Bing
author_facet Liu, Yongjin
Zhang, Bin
Yan, Bing
author_sort Liu, Yongjin
collection PubMed
description Anticancer drugs, such as paclitaxel (PTX), are indispensable for the treatment of a variety of malignancies. However, the application of most drugs is greatly limited by the low water solubility, poor permeability, or high efflux from cells. Nanoparticles have been widely investigated to enable drug delivery due to their low toxicity, sustained drug release, molecular targeting, and additional therapeutic and imaging functions. This review takes paclitaxel as an example and compares different nanoparticle-based delivery systems for their effectiveness in cancer chemotherapy.
format Online
Article
Text
id pubmed-3155358
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-31553582011-08-15 Enabling Anticancer Therapeutics by Nanoparticle Carriers: The Delivery of Paclitaxel Liu, Yongjin Zhang, Bin Yan, Bing Int J Mol Sci Review Anticancer drugs, such as paclitaxel (PTX), are indispensable for the treatment of a variety of malignancies. However, the application of most drugs is greatly limited by the low water solubility, poor permeability, or high efflux from cells. Nanoparticles have been widely investigated to enable drug delivery due to their low toxicity, sustained drug release, molecular targeting, and additional therapeutic and imaging functions. This review takes paclitaxel as an example and compares different nanoparticle-based delivery systems for their effectiveness in cancer chemotherapy. Molecular Diversity Preservation International (MDPI) 2011-07-07 /pmc/articles/PMC3155358/ /pubmed/21845085 http://dx.doi.org/10.3390/ijms12074395 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Liu, Yongjin
Zhang, Bin
Yan, Bing
Enabling Anticancer Therapeutics by Nanoparticle Carriers: The Delivery of Paclitaxel
title Enabling Anticancer Therapeutics by Nanoparticle Carriers: The Delivery of Paclitaxel
title_full Enabling Anticancer Therapeutics by Nanoparticle Carriers: The Delivery of Paclitaxel
title_fullStr Enabling Anticancer Therapeutics by Nanoparticle Carriers: The Delivery of Paclitaxel
title_full_unstemmed Enabling Anticancer Therapeutics by Nanoparticle Carriers: The Delivery of Paclitaxel
title_short Enabling Anticancer Therapeutics by Nanoparticle Carriers: The Delivery of Paclitaxel
title_sort enabling anticancer therapeutics by nanoparticle carriers: the delivery of paclitaxel
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155358/
https://www.ncbi.nlm.nih.gov/pubmed/21845085
http://dx.doi.org/10.3390/ijms12074395
work_keys_str_mv AT liuyongjin enablinganticancertherapeuticsbynanoparticlecarriersthedeliveryofpaclitaxel
AT zhangbin enablinganticancertherapeuticsbynanoparticlecarriersthedeliveryofpaclitaxel
AT yanbing enablinganticancertherapeuticsbynanoparticlecarriersthedeliveryofpaclitaxel